Sign In
Buy SGMO
$0.216
+0.0022 (+1.03%)
At Close: Jun 03, 2026
Sangamo Therapeutics' stock falls the most in 16 years after Pfizer ends Hemophilia pact
11:22am, Tuesday, 31'st Dec 2024
The small-cap won't receive an expected payout in the first quarter, creating a cash overhang.
Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact
11:20am, Tuesday, 31'st Dec 2024
Sangamo Therapeutics (SGMO) shares cratered more than 50% Tuesday, a day after the biopharma firm announced that Pfizer (PFE) had pulled out of its deal to co-develop a hemophilia drug.
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
09:14am, Tuesday, 31'st Dec 2024
On Monday, Sangamo Therapeutics, Inc. SGMO regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately sever
Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
08:47am, Tuesday, 31'st Dec 2024
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Tuesday.
SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate
07:10am, Tuesday, 31'st Dec 2024
Sangamo stock crashes 60.4% as partner Pfizer decides to end collaboration for hemophilia A candidate, giroctocogene fitelparvovec.
Sangamo Therapeutics down 50% premarket on Pfizer blow
06:06am, Tuesday, 31'st Dec 2024
Shares in Sangamo Therapeutics dropped 50% premarket after Pfizer Inc (NYSE:PFE, ETR:PFE) ended its collaboration on a gene therapy for haemophilia The drug, giroctocogene fitelparvovec, met its tar
Sangamo to reclaim hemophilia A therapy rights post Pfizer termination
04:34pm, Monday, 30'th Dec 2024
Sangamo Therapeutics said on Monday it would regain full rights to its hemophilia A gene therapy after co-development partner Pfizer terminated the agreement.
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A GENE THERAPY PROGRAM FOLLOWING PFIZER'S DECISION TO CEASE DEVELOPMENT.
Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development
02:48pm, Thursday, 19'th Dec 2024
Sangamo Therapeutics, Inc. received IND clearance to initiate a phase 1/2 study for ST-503 targeting idiopathic small fiber neuropathy, a type of chronic neuropathic pain condition. SGMO entered a dea
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
02:30am, Thursday, 19'th Dec 2024
- Agreement grants Astellas rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - - Sangamo to receive a $20 million upfront license fe
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR ST-503 FOR THE TREATMENT OF IDIOPATHIC SMALL FIBER NEUROPATHY.
Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript
09:25pm, Tuesday, 12'th Nov 2024
Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates
06:15pm, Tuesday, 12'th Nov 2024
Sangamo Therapeutics (SGMO) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.34 per share a year ago.
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
04:15pm, Monday, 04'th Nov 2024
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES THIRD QUARTER 2024 CONFERENCE CALL AND WEBCAST.
Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development
03:28pm, Wednesday, 23'rd Oct 2024
Positive Type B meeting held with FDA, whereby U.S. agency stated that the phase 1/2 STAAR study using isaralgagene civaparvovec targeting Fabry Disease patients would be enough for Accelerated Approv
